Shandong

我们是谁

  • 1 月 17, 2024
    A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
  • 1 月 17, 2024
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabine in Participants With Unresectable or Metastatic Colorectal Cancer
  • 1 月 10, 2024
    Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)
  • 1 月 9, 2024
    A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )
  • 7 月 26, 2022
    一项针对转移性结直肠癌晚期患者的 Nivolumab-relatlimab 固定剂量联合疗法对比瑞戈非尼或 TAS-102 的研究
  • 4 月 5, 2022
    KRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究(KRYSTAL-10)
  • 4 月 5, 2022
    A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (BREAKWATER)
  • 4 月 5, 2022
    Repotrectinib(TPX-0005)对携带 ALK、ROS1 或 NTRK1-3 基因重排的晚期实体瘤患者的研究